Study S000016

A Multiple-Dose Drug-Drug Interaction Study to Determine the Effect of LY3437943 on Drug Metabolizing Enzymes

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT05445232
Study type: INTERVENTIONAL
Allocation: NON_RANDOMIZED
Phase: PHASE1
Masking: NONE
Status: COMPLETED
Enrollment: 32
Start: 2022-07-08
Primary completion: 2023-02-24
Lead sponsor: Eli Lilly and Company
Conditions: Obesity
Interventions: DRUG:LY3437943; DRUG:Midazolam; DRUG:Warfarin; DRUG:Caffeine
Results posted: FALSE
Individual participant data sharing: NO
Secondary identifiers: OTHER:J1I-MC-GZBI

Registered primary outcomes

Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Midazolam [Predose up to 24 hours postdose]
PK: Maximum Observed Concentration (Cmax) of Midazolam [Predose up to 24 hours postdose]
PK: AUC[0-∞] of Warfarin [Predose up to 96 hours postdose]
PK: Cmax of Warfarin [Predose up to 96 hours postdose]
PK: AUC[0-∞] of Caffeine [Predose up to 48 hours postdose]
PK: Cmax of Caffeine [Predose up to 48 hours postdose]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.